Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (371-380 of 713) with videos related to

Pageof 72
Sort By:
Cancer|December 13, 2006
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapyAlfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia veraAlfonso Quintás-Cardama, Hagop Kantarjian, Taghi Manshouri, et al.
Cancer|October 2, 2010
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factorJorge Cortes, Alfonso Quintás-Cardama, Dan Jones, et al.
Cancer Medicine|September 11, 2019
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United StatesIman Abou Dalle, Hagop Kantarjian, Jan Burger, et al.
Blood|April 16, 2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaConstantine S Tam, Susan O'Brien, William Wierda, et al.
Cancer|September 16, 2003
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemiaJorge Cortes, Moshe Talpaz, Susan O'Brien, et al.
International Journal of Hematology|June 2, 2009
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001Roberto H Nussenzveig, Jorge Cortes, Matjaz Sever, et al.
Cancer|September 13, 2007
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 studyElias Jabbour, Hagop Kantarjian, Jorge Cortes, et al.
Cancer|October 2, 2009
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalitiesFarhad Ravandi, Jean-Pierre Issa, Guillermo Garcia-Manero, et al.
Cancer|July 1, 2011
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemiaJorge Cortes, Hagop Kantarjian, Edward D Ball, et al.
Pageof 72

Showing results (371-380 of 713) with videos related to

Sort By:
Pageof 72
Cancer|December 13, 2006
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapyAlfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia veraAlfonso Quintás-Cardama, Hagop Kantarjian, Taghi Manshouri, et al.
Cancer|October 2, 2010
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factorJorge Cortes, Alfonso Quintás-Cardama, Dan Jones, et al.
Cancer Medicine|September 11, 2019
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United StatesIman Abou Dalle, Hagop Kantarjian, Jan Burger, et al.
Blood|April 16, 2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaConstantine S Tam, Susan O'Brien, William Wierda, et al.
Cancer|September 16, 2003
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemiaJorge Cortes, Moshe Talpaz, Susan O'Brien, et al.
International Journal of Hematology|June 2, 2009
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001Roberto H Nussenzveig, Jorge Cortes, Matjaz Sever, et al.
Cancer|September 13, 2007
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 studyElias Jabbour, Hagop Kantarjian, Jorge Cortes, et al.
Cancer|October 2, 2009
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalitiesFarhad Ravandi, Jean-Pierre Issa, Guillermo Garcia-Manero, et al.
Cancer|July 1, 2011
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemiaJorge Cortes, Hagop Kantarjian, Edward D Ball, et al.
Pageof 72